logo

Axovant Sciences Ltd. (AXON)



Trade AXON now with
  Date
  Headline
2/12/2018 7:02:11 AM Axovant Sciences CEO David Hung Resigns To Pursue Other Opportunities
1/8/2018 7:09:24 AM Axovant: Intepirdine Did Not Meet Primary Efficacy Endpoints In Phase 2b HEADWAY, Pilot Phase 2 Gait And Balance Studies
9/26/2017 7:05:40 AM Axovant Sciences Announces Negative Topline Results Of Intepirdine Phase 3 MINDSET Trial In Alzheimer's Disease
8/17/2017 7:24:59 AM Race For A New Alzheimer's Drug
8/7/2017 7:23:54 AM Axovant Sciences Q1 Net Loss $69.3 Mln Or $0.65/Shr Vs Loss $38.06 Mln Or $0.38/Shr Lat Year
6/19/2017 7:06:00 AM FDA Grants Fast Track Designation To Axovant's Nelotanserin For Visual Hallucinations In Dementia With Lewy Bodies